Rasio cepet: Qiagen N.V. (QGEN)

The quick ratio demonstrates the immediate solvency of Qiagen N.V. (QGEN), where the latest reading stands at 2.26. The company's business model relies on the "razor-and-blade" principle, where equipment operates exclusively with proprietary reagents. Such a molecular diagnostic ecosystem creates high switching costs for customers. Stable revenue is ensured by the demand for consumables, despite potential fluctuations in academic budgets.

The ability of Qiagen N.V. (QGEN) to withstand external shocks depends on the availability of immediately accessible assets. Given the decline in revenues from COVID tests and costly developments in DNA analysis, maintaining a cash reserve is critically important. This metric excludes illiquid inventories, assessing the coverage of liabilities using only cash and accounts receivable. By analyzing the final quick ratio, an investor can determine the real solvency of the business without accounting for warehouse stocks.